NCT03439462View on ClinicalTrials.gov

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

August 16, 2022

Study Completion Date

August 26, 2022

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

nab-sirolimus

nab-sirolimus combined with mFOLFOX6 + bevacizumab

Trial Locations (6)

70121

Ochsner Clinic Foundation, New Orleans

75246

Baylor Scott and White University Medical Center, Dallas

85258

HonorHealth Research Institute, Scottsdale

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

98109

Seattle Cancer Care Alliance/University of Washington Medical Center, Seattle

07962

Atlantic Health System/Morristown Medical Center, Morristown

Sponsors
All Listed Sponsors
lead

Aadi Bioscience, Inc.

INDUSTRY

NCT03439462 - Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter